The results suggested an improvement in anti-tumor activity through a triple therapy combination of dabrafenib (BRAF inhibitor), trametinib (MEK inhibitor), and pembrolizumab (anti-PD-1 antibody). This evidence concerns the gene BRAF and neoplasm.